Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity.

Longitudinal follow-up analysis of 53 SARS-CoV-2 convalescent donors 4 months (T2, median sHLA class I 1.95 μg/mL, Table S2 ) after the first sample collection (T1, median sHLA class I 2.29 μg/mL) revealed a persisting increase of sHLA class I serum levels ( Figure 1 B, p = 0.3742) compared to the healthy control cohort with a decreasing trend over time ( Figure 1 C).

also in 47,180 other papers